Epoxylipids and soluble epoxide hydrolase in heart diseases

0556810 - FGÚ 2023 RIV US eng J - Článek v odborném periodiku
Imig, J. D. - Červenka, L. - Neckář, Jan
Epoxylipids and soluble epoxide hydrolase in heart diseases.
Biochemical Pharmacology. Roč. 195, Jan (2022), č. článku 114866. ISSN 0006-2952. E-ISSN 1873-2968
Grant CEP: GA ČR(CZ) GA18-03207S
Institucionální podpora: RVO:67985823
Klíčová slova: eicosanoids * cytochrome P450 * soluble epoxide hydrolase * hypertension * heart failure * myocardial infarction * inflammation * mitochondrial function * coronary artery
Obor OECD: Physiology (including cytology)
Impakt faktor: 5.8, rok: 2022
Způsob publikování: Omezený přístup
https://doi.org/10.1016/j.bcp.2021.114866

Cardiovascular and heart diseases are leading causes of morbidity and mortality. Coronary artery endothelial and vascular dysfunction, inflammation, and mitochondrial dysfunction contribute to progression of heart diseases such as arrhythmias, congestive heart failure, and heart attacks. Classes of fatty acid epoxylipids and their enzymatic regulation by soluble epoxide hydrolase (sEH) have been implicated in coronary artery dysfunction, inflammation, and mitochondrial dysfunction in heart diseases. Likewise, genetic and pharmacological manip-ulations of epoxylipids have been demonstrated to have therapeutic benefits for heart diseases. Increasing epoxylipids reduce cardiac hypertrophy and fibrosis and improve cardiac function. Beneficial actions for epox-ylipids have been demonstrated in cardiac ischemia reperfusion injury, electrical conductance abnormalities and arrhythmias, and ventricular tachycardia. This review discusses past and recent findings on the contribution of epoxylipids in heart diseases and the potential for their manipulation to treat heart attacks, arrhythmias, ven-tricular tachycardia, and heart failure.
Trvalý link: http://hdl.handle.net/11104/0331112